Display options
Cite
Stewart ZA, Stern J, Ali NM, et al. Clinical and Financial Implications of 2 Treatment Strategies for Donor-derived Hepatitis C Infections. Transplant Direct. 2021;7(10):e762doi: 10.1097/TXD.0000000000001222.
Stewart, Z. A., Stern, J., Ali, N. M., Kalia, H. S., Khalil, K., Jonchhe, S., Weldon, E. P., Dieter, R. A., Lewis, T. C., Funches, N., Crosby, S., Seow, M., Berger, J. C., Dagher, N. N., Gelb, B. E., Watkins, A. C., Moazami, N., Smith, D. E., Kon, Z. N., Chang, S. H., Reyentovich, A., Angel, L. F., Montgomery, R. A., & Lonze, B. E. (2021). Clinical and Financial Implications of 2 Treatment Strategies for Donor-derived Hepatitis C Infections. Transplantation direct, 7(10), e762. https://doi.org/10.1097/TXD.0000000000001222
Stewart, Zoe A, et al. "Clinical and Financial Implications of 2 Treatment Strategies for Donor-derived Hepatitis C Infections." Transplantation direct vol. 7,10 (2021): e762. doi: https://doi.org/10.1097/TXD.0000000000001222
Stewart ZA, Stern J, Ali NM, Kalia HS, Khalil K, Jonchhe S, Weldon EP, Dieter RA, Lewis TC, Funches N, Crosby S, Seow M, Berger JC, Dagher NN, Gelb BE, Watkins AC, Moazami N, Smith DE, Kon ZN, Chang SH, Reyentovich A, Angel LF, Montgomery RA, Lonze BE. Clinical and Financial Implications of 2 Treatment Strategies for Donor-derived Hepatitis C Infections. Transplant Direct. 2021 Sep 07;7(10):e762. doi: 10.1097/TXD.0000000000001222. eCollection 2021 Oct. PMID: 34514117; PMCID: PMC8425828.
Copy Download .nbib Format: NLM
Share it on

Transplant Direct. 2021 Sep 07;7(10):e762. doi: 10.1097/TXD.0000000000001222. eCollection 2021 Oct.

Clinical and Financial Implications of 2 Treatment Strategies for Donor-derived Hepatitis C Infections.

Transplantation direct

Zoe A Stewart, Jeffrey Stern, Nicole M Ali, Harmit S Kalia, Karen Khalil, Srijana Jonchhe, Elaina P Weldon, Rebecca A Dieter, Tyler C Lewis, Nur Funches, Sudara Crosby, Monique Seow, Jonathan C Berger, Nabil N Dagher, Bruce E Gelb, Anthony C Watkins, Nader Moazami, Deane E Smith, Zachary N Kon, Stephanie H Chang, Alex Reyentovich, Luis F Angel, Robert A Montgomery, Bonnie E Lonze

Affiliations

  1. Transplant Institute, NYU Langone Health, New York, NY.
  2. Department of Cardiothoracic Surgery, Northwell Health, Manhasset, NY.

PMID: 34514117 PMCID: PMC8425828 DOI: 10.1097/TXD.0000000000001222

Abstract

Transplanting hepatitis C viremic donor organs into hepatitis C virus (HCV)-negative recipients is becoming increasingly common; however, practices for posttransplant direct-acting antiviral (DAA) treatment vary widely. Protracted insurance authorization processes for DAA therapy often lead to treatment delays.

METHODS: At our institution, 2 strategies for providing DAA therapy to HCV

RESULTS: One hundred fifty-two transplants were performed using HCV viremic donor organs. Eighty-nine patients received DAA treatment without subsidy, and 62 received DAA treatment with subsidy. One patient who never developed viremia posttransplant received no treatment. Subsidizing the initial course enabled earlier treatment initiation (median, 4 d [interquartile range (IQR), 2-7] vs 10 [IQR, 8-13];

CONCLUSIONS: Recipients and their caregivers stand to benefit from earlier DAA treatment initiation; however, institutional costs to subsidize DAA therapy before insurance authorization are substantial. Insurance authorization processes for DAAs should be revised to accommodate this unique patient group.

Copyright © 2021 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.

Conflict of interest statement

The authors declare no funding or conflicts of interest.

References

  1. Transplantation. 2018 Dec;102(12):2088-2095 - PubMed
  2. Transpl Infect Dis. 2020 Feb;22(1):e13204 - PubMed
  3. Hepatology. 2020 Feb;71(2):686-721 - PubMed
  4. Ann Hepatol. 2021 Sep-Oct;24:100318 - PubMed
  5. Lancet Gastroenterol Hepatol. 2019 Oct;4(10):771-780 - PubMed
  6. Am J Transplant. 2019 Nov;19(11):2969-2970 - PubMed
  7. Am J Transplant. 2020 Feb;20(2):600-605 - PubMed
  8. Clin Transplant. 2020 Sep;34(9):e13989 - PubMed
  9. Transpl Infect Dis. 2021 Feb;23(1):e13449 - PubMed
  10. Transpl Infect Dis. 2019 Dec;21(6):e13194 - PubMed
  11. Am J Transplant. 2020 Mar;20(3):739-751 - PubMed
  12. Hepatology. 2019 Jun;69(6):2381-2395 - PubMed
  13. Am J Transplant. 2019 Nov;19(11):3046-3057 - PubMed
  14. Am J Transplant. 2021 May;21(5):1931-1936 - PubMed
  15. J Hepatol. 2021 Apr;74(4):873-880 - PubMed
  16. Ann Intern Med. 2018 Apr 17;168(8):533-540 - PubMed
  17. N Engl J Med. 2019 Apr 25;380(17):1606-1617 - PubMed
  18. J Heart Lung Transplant. 2020 Jul 8;: - PubMed
  19. N Engl J Med. 2017 Jun 15;376(24):2394-2395 - PubMed
  20. Transplantation. 2021 Aug 1;105(8):1850-1857 - PubMed
  21. MMWR Morb Mortal Wkly Rep. 2016 Dec 30;65(50-51):1445-1452 - PubMed
  22. Transpl Infect Dis. 2020 Dec;22(6):e13402 - PubMed
  23. JAMA Cardiol. 2020 Feb 1;5(2):167-174 - PubMed
  24. Kidney360. 2020 Nov;1(11):1291-1299 - PubMed
  25. Clin Transplant. 2020 Oct;34(10):e14030 - PubMed
  26. J Hepatol. 2018 Nov;69(5):1188-1196 - PubMed
  27. Transplant Direct. 2020 Nov 10;6(12):e627 - PubMed
  28. Am J Respir Crit Care Med. 2018 Jun 1;197(11):1492-1496 - PubMed
  29. Open Forum Infect Dis. 2018 Jun 07;5(6):ofy076 - PubMed
  30. Am J Transplant. 2017 Nov;17(11):2790-2802 - PubMed
  31. J Heart Lung Transplant. 2019 Dec;38(12):1259-1267 - PubMed
  32. Ann Intern Med. 2018 Sep 4;169(5):273-281 - PubMed
  33. Am J Transplant. 2019 May;19(5):1380-1387 - PubMed

Publication Types